Literature DB >> 29356078

Diabetes and technology in 2030: a utopian or dystopian future?

D Kerr1, C Axelrod1, C Hoppe1, D C Klonoff1.   

Abstract

The ability of an individual living with diabetes to have human-to-human contact with their healthcare provider is not keeping pace with the number of people developing diabetes. From a futurist perspective, however, this dichotomy of diabetes care represents an opportunity for digital healthcare. The focus of technological innovation is unlikely to be the replacement of the multidisciplinary diabetes team but rather the provision of meaningful individual and family support between clinic visits and, on a larger scale, the facilitation of population health management for diabetes. We can also expect to see new therapies, including implantable drug delivery systems, automated closed-loop systems and miniaturized non-invasive glucose monitoring systems. New digital health technologies will create a 'digital diabetes ecosystem' to enhance rather than devolve care from humans. Concerns related to data privacy and ownership will inevitably rise, thus a future for diabetes care relying heavily on technology is not inevitably utopian. Nevertheless, revolutions in the development of novel sensors, accumulation of 'big data', and use of artificial intelligence will provide exciting opportunities for preventing, monitoring and treating diabetes in the near future.
© 2018 Diabetes UK.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29356078     DOI: 10.1111/dme.13586

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  10 in total

1.  Smart Pens Will Improve Insulin Therapy.

Authors:  David C Klonoff; David Kerr
Journal:  J Diabetes Sci Technol       Date:  2018-02-07

2.  Clouds and Silver Linings: COVID-19 Pandemic Is an Opportune Moment to Democratize Diabetes Care Through Telehealth.

Authors:  David Kerr; Hope Warshaw
Journal:  J Diabetes Sci Technol       Date:  2020-10-13

3.  Diabetes Healthcare Professionals Use Multiple Continuous Glucose Monitoring Data Indicators to Assess Glucose Management.

Authors:  Tong Sheng; Reid Offringa; David Kerr; Mark Clements; Jerome Fischer; Linda Parks; Michael Greenfield
Journal:  J Diabetes Sci Technol       Date:  2019-09-06

4.  Digital Diabetes Data and Artificial Intelligence: A Time for Humility Not Hubris.

Authors:  David Kerr; David C Klonoff
Journal:  J Diabetes Sci Technol       Date:  2018-09-05

5.  Level of Digitalization in Germany: Results of the Diabetes Digitalization and Technology (D.U.T) Report 2020.

Authors:  Timm Roos; Sabine Hochstadt; Winfried Keuthage; Jens Kröger; Andreas Lueg; Hansjörg Mühlen; Lisa Schütte; Nikolaus Scheper; Dominic Ehrmann; Norbert Hermanns; Lutz Heinemann; Bernhard Kulzer
Journal:  J Diabetes Sci Technol       Date:  2020-10-27

6.  Digital Connectivity: The Sixth Vital Sign.

Authors:  David C Klonoff; Trisha Shang; Jennifer Y Zhang; Eda Cengiz; Chhavi Mehta; David Kerr
Journal:  J Diabetes Sci Technol       Date:  2021-05-12

Review 7.  Multisensor Systems and Arrays for Medical Applications Employing Naturally-Occurring Compounds and Materials.

Authors:  Rasa Pauliukaite; Edita Voitechovič
Journal:  Sensors (Basel)       Date:  2020-06-23       Impact factor: 3.576

8.  Digital Diabetes Care System Observations from a Pilot Evaluation Study in Vietnam.

Authors:  Tran Quang Khanh; Pham Nhu Hao; Eytan Roitman; Itamar Raz; Baruch Marganitt; Avivit Cahn
Journal:  Int J Environ Res Public Health       Date:  2020-02-03       Impact factor: 3.390

Review 9.  Conversational Agents in Health Care: Scoping Review and Conceptual Analysis.

Authors:  Lorainne Tudor Car; Dhakshenya Ardhithy Dhinagaran; Bhone Myint Kyaw; Tobias Kowatsch; Shafiq Joty; Yin-Leng Theng; Rifat Atun
Journal:  J Med Internet Res       Date:  2020-08-07       Impact factor: 5.428

Review 10.  Leveraging advances in diabetes technologies in primary care: a narrative review.

Authors:  Bruce Bode; Aaron King; David Russell-Jones; Liana K Billings
Journal:  Ann Med       Date:  2021-12       Impact factor: 4.709

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.